LGR5 and colitis: In the progression from colitis to colorectal cancer, targeted inhibition of MUC1-C plays a crucial role in blocking LGR5+ intestinal stem cells (ISCs), Myc, and pluripotency factors signaling pathways, slowing down the worsening of colitis (10).